Teriparatide outperforms alendronate in treating steroid-induced osteoporosis

October 29, 2009

A recent study determined glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, a synthetic form of the human parathyroid hormone. Researchers found patients with glucocorticoid-induced OP who were treated with teriparatide for 36 months had a greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate. The findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

Glucocorticoids are steroid hormones that are naturally produced in the body or synthetically created compounds (drugs) used to reduce inflammation. These steroid drugs are used to control inflammation in patients with such autoimmune diseases as rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease as well as inflammatory conditions such as asthma. Glucocorticoid-induced osteoporosis occurs when patients taking steroid medications such as prednisone, prednisolone, dexamethasone, and cortisone exhibit reduced bone mass and bone strength.

This 36-month, randomized, double-blind, controlled trial, led by Kenneth Saag, M.D., from the University of Alabama, was conducted at 76 centers located in 13 countries. A total of 428 patients between the ages of 22-89 with confirmed OP who had received greater than 5 mg/day of prednisone or equivalent for more than 3 months preceding screening were included. Research measures included changes in lumbar spine and hip bone, BMD, changes in bone biomarkers, fracture incidence, and safety.

Study participants were randomly assigned to receive injectable teriparatide (20 μg/day) plus oral placebo (150 subjects) or oral alendronate (10 mg/day) plus injectable placebo (144 subjects). Supplements of calcium (1,000 mg/day) and vitamin D (800 IU/day) were provided to all study participants. Subjects kept a daily journal to record their steroid use.

Results show at 36 months the BMD for lumbar spine was 11% higher than baseline in the teriparatide group compared with 5.3% in the alendronate group. The BMD (teriparatide versus alendronate) for total hip was 5.2% versus 2.7% and 6.3% versus 3.4% for femoral neck. Researchers also observed fewer vertebral fractures in subjects taking teriparatide (1.7%) than those administered alendronate (7.7%). Higher levels of calcium concentrations were noted in the teriparatide group (21%) than in the alendronate group (7%).

"There is a significant number of individuals who are regularly treated with steroids to control inflammation which puts them at risk for developing osteoporosis. A need for therapies that mitigate this side-effect of steroid use and substantially improves bone mass is vital," commented Dr. Saag. The ACR estimates that diseases commonly treated with (cortico)steroids may affect more than 30 million Americans. "Our research shows that teriparatide is a safe and effective treatment for patients with steroid-induced OA and should be considered as a therapeutic option for those at high risk of bone fracture," recommended Dr. Saag.
-end-
Article: "Effects of Teriparatide Versus Alendronate for Treating Glucocorticoid-Induced Osteoporosis." Kenneth G. Saag, Jose R. Zanchetta, Jean-Pierre Devogelaer, Robert A. Adler, Richard Eastell, Kyoungah See, John H. Krege, Kelly Krohn, and Margaret R. Warner. Arthritis & Rheumatism; Published Online: October 29, 2009 (DOI 10.1002/art.24879); Print Issue Date: November 2009

Wiley

Related Bone Mineral Density Articles from Brightsurf:

Romosozumab substantially builds bone density in hip and spine
New research presented at ACR Convergence, the American College Rheumatology's annual meeting, reveals that romosozumab, an osteoporosis drug, produces substantial gains in bone mineral density in the hip and lumbar spine within one year, and that transitioning patients to a potent antiresorptive drug can lead to even more bone density gains.

Bone density is associated with regular use, study finds
Researchers at the Beckman Institute at the University of Illinois Urbana-Champaign have found that bone density and frame size of women is associated with habitual use in tasks that involve domestic labor.

New guidelines for assessment of bone density and microarchitecture in vivo with HR-pQCT
There is an urgent need for guidance and consensus on the methods for, and reporting of, high-resolution peripheral quantitative computed tomography (HR-pQCT) imaging so that different studies can be compared to each other.

Adults with undiagnosed Celiac disease have lower bone density, says first study on topic
Research by George Mason University College of Health and Human Services found lower bone density in adults who are likely to have undiagnosed celiac disease, an autoimmune disease triggered by consuming gluten, despite this group consuming more calcium and phosphorous than the control group.

Family history of diabetes linked to increased bone mineral density
The association between type 2 diabetes and increased fracture risk is well documented.

Lower than expected risk of bone density decline with Truvada PrEP
Researchers have shown that among users of pre-exposure prophylaxis (PrEP) to prevent against AIDS that includes tenofovir (Truvada), those with daily use -- very high adherence -- had only about a 1% average decrease in bone mineral density in the spine and a 0.5% decline in the hip.

Study supports bisphosphonate use prior to denosumab to prevent loss of bone mineral density in post-menopausal women
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) finds the risk of bone mineral density (BMD) loss after denosumab discontinuation is associated with younger age, high bone turnover markers, and not receiving the bisphosphonate, zoledronate, prior to initiation of denosumab.

Sex-specific effects of DHEA on bone mineral density and body composition
Women 55 and older have an increased risk of bone and muscle loss but therapy with the hormone Dehydroepiandrosterone (DHEA) may help prevent bone loss and increase muscle mass in older women, according to a new study led by Catherine M.

Beyond bone mineral density: Additional bone traits predict risk for fracture
In the largest prospective study of its kind, researchers from Beth Israel Deaconess Medical Center (BIDMC) and the Institute for Aging Research at Hebrew SeniorLife used high-resolution tomography imaging to assess whether bone characteristics besides bone mineral density can predict risk of fracture.

A fracture anywhere reduces bone density everywhere
New studies from UC Davis Health are among the first to associate fractures with systemic bone loss.

Read More: Bone Mineral Density News and Bone Mineral Density Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.